Stay updated with breaking news from Efung Capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Key Takeaways: Sunho Biologics has no revenue or licensing income to draw on, making a loss of 133 million yuan last year as all its products remain at the R&D or clinical stage
:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/thenational/OZ7WSV2L27E4UQ3AHDDF3WLTN4.jpg)
Transaction marks the company’s first controlling buyout in world's second largest economy
IASO previously completed a $60m Series B financing round led by GL Ventures in March 2020.
/PRNewswire/ -- IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative...
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!